Literature DB >> 7038373

Chronic necrotizing pulmonary aspergillosis: a discrete clinical entity.

R E Binder, L J Faling, R D Pugatch, C Mahasaen, G L Snider.   

Abstract

We conclude that chronic necrotizing pulmonary aspergillosis is a clinical entity which has not usually been recognized as one of the forms of pulmonary disease due to Aspergillus species. Patients are middle-aged, and often have some evidence of impairment of host defenses such as diabetes mellitus, a connective tissue disorder, poor nutrition, chronic obstructive lung disease or low dose corticosteroid therapy. They are almost always symptomatic with fever and a productive cough, and their chest roentgenogram shows infiltrative and cavitary disease, typical of a chronic destructive lung process such as tuberculosis or anaerobic infection. Cavity formation is often accompanied by the development of a mycetoma. The disease is usually of 1 to 6 months duration but can be present for years prior to diagnosis. The diagnosis is suggested by the clinical course and the isolation of the fungus from pulmonary secretions; negative cultures for other pathogens and failure to respond to antibacterial or antimycobacterial therapy are characteristic. The diagnosis is confirmed by pathologic evidence of tissue invasion by the fungus or a response to specific antimycotic therapy. The symptomatic response to antifungal chemotherapy, at times combined with surgical drainage or resection, is favorable. However, roentgenographic resolution is not uniform, and many patients have residual cavitary disease. The long-term prognosis is uncertain.

Entities:  

Mesh:

Year:  1982        PMID: 7038373     DOI: 10.1097/00005792-198203000-00005

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  48 in total

1.  Effects of Aspergillus fumigatus culture filtrate on antifungal activity of human phagocytes in vitro.

Authors:  T Murayama; R Amitani; Y Ikegami; R Kawanami; W J Lee; R Nawada
Journal:  Thorax       Date:  1998-11       Impact factor: 9.139

2.  Chronic necrotising pulmonary aspergillosis caused by Aspergillus niger in a mildly immunocompromised host.

Authors:  M Yamaguchi; H Nishiya; K Mano; O Kunii; H Miyashita
Journal:  Thorax       Date:  1992-07       Impact factor: 9.139

Review 3.  Pulmonary aspergillosis: clinical presentation, diagnostic tests, management and complications.

Authors:  Rami Sherif; Brahm H Segal
Journal:  Curr Opin Pulm Med       Date:  2010-05       Impact factor: 3.155

4.  Rapid occurrence of pulmonary aspergillosis after pulmonary wedge resection.

Authors:  Fengshi Chen; Shinichi Itoi; Takeo Hirata; Koji Chihara
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2004-12

5.  Corticosteroid treatment as a risk factor for invasive aspergillosis in patients with lung disease.

Authors:  L B Palmer; H E Greenberg; M J Schiff
Journal:  Thorax       Date:  1991-01       Impact factor: 9.139

6.  Ward Round: a jaundiced 43 year old man with cavitary lessions on chest radiograph.

Authors:  T Hartung; J van Oosterhout
Journal:  Malawi Med J       Date:  2007-09       Impact factor: 0.875

7.  Rapid immunoelectrophoretic assay for detection of serum antibodies to Aspergillus fumigatus catalase in patients with pulmonary aspergillosis.

Authors:  H Schønheyder; P Andersen; J C Petersen
Journal:  Eur J Clin Microbiol       Date:  1985-06       Impact factor: 3.267

8.  Chronic necrotising pulmonary aspergillosis treated with itraconazole.

Authors:  J A Elliott; L J Milne; D Cumming
Journal:  Thorax       Date:  1989-10       Impact factor: 9.139

9.  Purification and characterization of factors produced by Aspergillus fumigatus which affect human ciliated respiratory epithelium.

Authors:  R Amitani; G Taylor; E N Elezis; C Llewellyn-Jones; J Mitchell; F Kuze; P J Cole; R Wilson
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

10.  Invasive aspergillosis in a "healthy" patient.

Authors:  K J Ascah; R H Hyland; M A Hutcheon; S J Urbanski; W Pruzanski; E L St Louis; D P Jones; E C Keystone
Journal:  Can Med Assoc J       Date:  1984-08-15       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.